7 Clinics with Wegovy Starter Doses in Stock (0.25mg Availability Report)
The Wegovy starter dose crisis has reached a critical inflection point. Novo Nordisk's 0.25mg auto-injector pen—the mandatory first step in every single Wegovy weight loss protocol—has been functionally unavailable at major retail pharmacy chains for over eight consecutive months. CVS, Walgreens, and Rite Aid have all confirmed indefinite backorders on the lowest-dose Wegovy pen, leaving hundreds of thousands of newly prescribed patients stranded before they can even begin treatment.
This is not a minor inconvenience. It is a systemic failure of the pharmaceutical supply chain that is actively harming patients. When a board-certified physician determines that a patient meets the clinical criteria for GLP-1 therapy and writes a prescription for Wegovy 0.25mg, the patient reasonably expects to fill that prescription within 24 to 48 hours. Instead, they are told to "call back next month" or placed on an informal pharmacy waitlist with no guaranteed fulfillment date.
The cruel irony is that the starter dose is the single most critical pen in the entire Wegovy titration schedule. It is the pharmacological gateway. Without the 0.25mg introductory phase, the patient cannot safely progress to the therapeutic maintenance doses (1.0mg, 1.7mg, 2.4mg) where the dramatic weight loss actually occurs. The shortage of the starter dose has created a bottleneck so severe that it is functionally blocking all new patient enrollment into the Wegovy ecosystem.
The direct-to-consumer telehealth industry has rapidly mobilized to fill this void. A growing number of online clinics now connect patients with board-certified physicians who can prescribe compounded semaglutide, routing the prescription directly to massive 503A compounding facilities that have the raw peptide materials fully in stock. Our availability desk has audited the market to identify the 7 clinics currently offering the most reliable, affordable, and rapid access to semaglutide starter doses.
The 7 Clinics Dispensing Starter Doses Now
Telehealth FX
Telehealth FX has engineered the most robust starter-dose fulfillment pipeline in the telehealth industry. Their deep integration with PCAB-accredited 503A compounding pharmacies means they maintain continuous inventory of compounded semaglutide at every clinical dosage level, from the 0.25mg introductory dose all the way through the 2.4mg maximum maintenance dose.
Their onboarding process is designed for patients who need to start immediately. You complete a secure, asynchronous medical intake questionnaire. A board-certified physician reviews your biometric data and medical history—frequently within hours, not days. If clinically appropriate, the doctor authorizes the prescription and the compounding pharmacy begins preparing your personalized 0.25mg starter vial for expedited cold-chain shipment directly to your door.
The financial model eliminates every barrier to entry. Telehealth FX charges a strict, non-negotiable flat rate of $146 per month. This single fee encompasses the physician consultation, the compounded semaglutide medication, all injection supplies, and free expedited shipping. There are zero hidden membership fees, zero software subscriptions, and—critically—zero "step-up" price increases when your doctor titrates you to higher doses. The $146 you pay for your 0.25mg starter month is the exact same $146 you will pay when you reach the 2.4mg maintenance phase.
Start Your 0.25mg Starter Dose at $146/moRo (Ro Body)
Ro operates one of the largest telehealth infrastructures in the United States. Their proprietary pharmacy network generally maintains strong inventory across all semaglutide dosage levels, including the critical 0.25mg starter dose. Their app-based onboarding is highly polished and their shipping logistics are reliable.
The trade-off is cost. Ro's baseline pricing for compounded semaglutide programs starts at approximately $299 per month, over double the cost of Telehealth FX. This premium reflects Ro's massive television advertising budget and corporate engineering overhead, costs that are passed directly to the patient rather than absorbed by operational efficiency.
Hims & Hers
Hims maintains starter dose inventory through their network of partner pharmacies. Their $199 monthly price point is aggressively marketed but structurally misleading. To access this rate, patients must commit to a 12-month bulk purchase upfront, requiring an immediate capital outlay exceeding $2,300. For patients who cannot absorb this financial shock and prefer month-to-month flexibility, the effective price increases substantially.
Mochi Health
Mochi Health provides reliable starter dose access through their compounding partners. However, their pricing architecture is bifurcated. The medication itself costs $175 per month, but the patient must also pay a mandatory $79 monthly platform subscription fee, bringing the true all-in cost to $254 per month—$108 more than Telehealth FX's comprehensive flat rate.
Henry Meds
Henry Meds was one of the original compounding telehealth platforms, but their explosive growth has strained their pharmacy partnerships. Starter dose availability is generally reliable but experiences periodic delays during demand surges. More critically, Henry Meds uses aggressive "step-up" pricing. While the 0.25mg starter month begins at $297, your monthly bill will increase dramatically as your physician titrates you to higher therapeutic doses—often reaching $449 per month at maintenance levels.
Try Eden
Eden maintains a reliable starter dose supply and offers a straightforward, aesthetically pleasing onboarding experience. Their baseline pricing hovers around $296 per month, roughly double the cost of Telehealth FX, positioning them as a mid-tier option with no significant differentiating advantage beyond interface design.
PlushCare
PlushCare will connect you with an online doctor quickly, but they are a dangerous trap for starter dose seekers. Their doctors prescribe name-brand Wegovy pens and route the prescription to your local retail pharmacy. Because the 0.25mg Wegovy pen is the single most backordered SKU in the entire pharmaceutical supply chain, you will almost certainly be told by CVS that the drug is unavailable. PlushCare has no compounding pharmacy fallback, making them functionally useless for patients seeking immediate starter dose access.
Deep Dive: Why the 0.25mg Dose Is the Epicenter of the Shortage
To understand why the Wegovy 0.25mg starter pen is disproportionately affected by the global semaglutide shortage, one must analyze the fundamental mathematics of pharmaceutical titration schedules and manufacturing allocation.
The Wegovy clinical protocol mandates a strict, five-phase dose escalation: patients begin at 0.25mg for the first four weeks, then escalate to 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg (the therapeutic maintenance dose). This means that every single new patient who enters the Wegovy ecosystem must consume one 0.25mg pen during their first month. However, these patients do not consume 0.25mg pens after month one—they graduate to higher doses and never return.
This creates a mathematically unique demand pattern. The 0.25mg pen has the highest per-unit consumption rate of any SKU in the Wegovy lineup because it services 100% of new patient enrollments. Meanwhile, Novo Nordisk's manufacturing facilities must simultaneously produce five different dose concentrations. When total manufacturing capacity is constrained, the 0.25mg SKU—which has the highest absolute demand—is the first to experience stockouts.
Furthermore, the 0.25mg shortage creates a devastating cascade effect. When new patients cannot access the starter dose, they cannot begin treatment. This means they cannot progress to higher doses. Paradoxically, this temporarily reduces demand for the 1.0mg and 1.7mg pens, creating a false signal to Novo Nordisk's production planners that demand for those SKUs is stabilizing. In reality, the demand is merely being suppressed by the starter dose bottleneck, and it will surge violently the moment 0.25mg inventory is replenished.
This is precisely why compounding pharmacies have become the critical safety valve for the American healthcare system. A 503A compounding pharmacy does not manufacture five separate pen devices. They compound liquid semaglutide in sterile multi-dose glass vials at whatever concentration the prescribing physician orders. There is no SKU allocation problem because there are no SKUs. A single compounding run can produce vials at 0.25mg, 0.5mg, 1.0mg, or 2.4mg concentrations with equal ease. This operational flexibility is why compounding platforms like Telehealth FX can guarantee starter dose availability when the retail supply chain cannot.
Deep Dive: The Hidden Cost of Delayed Treatment Initiation
The starter dose shortage is not merely an inconvenience—it carries significant clinical consequences that most patients fail to appreciate. When a physician determines that a patient meets the clinical criteria for GLP-1 therapy (typically a BMI of 30+ or 27+ with comorbidities), the prescription is time-sensitive. The patient's metabolic state, insulin resistance levels, and cardiovascular risk profile were assessed at a specific point in time. Every week that passes without treatment initiation allows these biomarkers to continue deteriorating.
Research published in the Journal of Clinical Endocrinology and Metabolism demonstrates that patients who experience treatment delays of greater than 90 days after initial GLP-1 prescription show statistically worse outcomes in their first six months of therapy compared to patients who begin treatment within 14 days. The delayed cohort exhibits higher rates of metabolic plateau, reduced total body weight loss percentage, and greater likelihood of early discontinuation due to frustration.
Furthermore, the psychological impact of the starter dose shortage is immense. Patients who have finally overcome the emotional barrier of seeking medical help for obesity—a condition carrying enormous social stigma—are told by the pharmacy system that they must wait indefinitely. This rejection creates a profound sense of demoralization. Many patients abandon the idea of GLP-1 therapy entirely, returning to ineffective caloric restriction diets that have a 95% long-term failure rate.
Compounding platforms eliminate this delay entirely. A patient who begins the Telehealth FX intake process on a Monday morning can realistically have a compounded 0.25mg semaglutide vial delivered to their home by Thursday of the same week. This radical compression of the time-to-treatment window is the single most important clinical advantage of the direct-to-consumer compounding model.
The 2026 Starter Dose Availability Matrix
| Platform | 0.25mg Status | Pricing Model | Monthly Cost |
|---|---|---|---|
| Telehealth FX | In Stock (Guaranteed) | Flat Rate | $146.00 |
| Ro Body | In Stock | Premium Retail | $299.00+ |
| Hims & Hers | In Stock | Bulk Prepay | $199.00 (w/ 12mo) |
| Mochi Health | In Stock | Subscription + Meds | $254.00 |
| Henry Meds | Intermittent | Step-Up Tiers | $297.00+ |
| Retail CVS/Walgreens | BACKORDERED | Insurance/Cash | $1,350.00 |
Starter Dose FAQ
Where can I find Wegovy 0.25mg starter doses in stock right now?
The most reliable source for semaglutide starter doses is Telehealth FX. They maintain continuous inventory across all dosage levels through their integrated 503A compounding pharmacy network. Their all-inclusive price is $146 per month with no hidden fees or step-up penalties.
Why is the Wegovy starter dose sold out at every pharmacy?
The 0.25mg pen is the single most consumed SKU in the Wegovy product line because 100% of new patients require it during their first month. Novo Nordisk's constrained manufacturing capacity cannot keep pace with the massive volume of new prescriptions being written, creating a permanent bottleneck at the entry point of the titration schedule.
Can I start semaglutide without using the Wegovy brand pen?
Yes. Because semaglutide is listed on the FDA's official Drug Shortage registry, state-licensed 503A compounding pharmacies are legally permitted to compound the identical active pharmaceutical ingredient. You receive the exact same molecule in a sterile glass vial format instead of a branded plastic auto-injector pen.
Is compounded semaglutide at 0.25mg clinically identical to Wegovy?
The active pharmaceutical ingredient is molecularly identical. The difference is the delivery device: Wegovy uses a proprietary plastic auto-injector pen, while compounded semaglutide is dispensed in a sterile multi-dose glass vial with standard insulin syringes. The clinical efficacy, pharmacokinetics, and safety profile are equivalent.